Kalinin Iu T, Vorob'ev A A, Bumialis V V, Denisov L A, Parfenov V V, Klenova A V, Ianulaĭtis A A, Ershov F I, Marchenko V I, Malinovskaia V V
Zh Mikrobiol Epidemiol Immunobiol. 1990 Sep(9):61-7.
The results of the clinical trials of human recombinant interferon alpha-2 (reaferon) make it possible to come to the conclusion that the preparation is well-tolerated and produces a pronounced therapeutic effect in a number of viral and oncological diseases. The Pharmacological Committee of the USSR has recommended reaferon for use in acute hepatitis B, hairy cell leukemia, renal cancer at stage IV, disseminated sclerosis, ocular herpes. The use of reaferon has been found to be promising in the treatment of papillomatosis of the larynx, Kaposi's sarcoma, mycosis fungoides, chronic myeloleukemia.
人重组干扰素α-2（干复津）的临床试验结果表明，该制剂耐受性良好，对多种病毒性疾病和肿瘤疾病具有显著的治疗效果。苏联药理学委员会已推荐干复津用于治疗急性乙型肝炎、毛细胞白血病、IV期肾癌、播散性硬化症、眼部疱疹。已发现干复津在治疗喉乳头状瘤病、卡波西肉瘤、蕈样肉芽肿、慢性粒细胞白血病方面具有应用前景。
